| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:36 UTC |
|---|
| HMDB ID | HMDB0014393 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Cabergoline |
|---|
| Description | Cabergoline is only found in individuals that have used or taken this drug. It is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors. The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, alpha1,- and alpha2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. |
|---|
| Structure | [H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | ChEBI | | (8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide | ChEBI | | 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | ChEBI | | 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | ChEBI | | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea | ChEBI | | Cabergolina | ChEBI | | Cabergolinum | ChEBI | | Cabaser | Kegg | | Dostinex | Kegg | | (8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | Generator | | (8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | Generator | | 1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | Generator | | 1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | Generator | | 1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | Generator | | 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | Generator | | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea | Generator | | 1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea | Generator | | 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate | HMDB | | Cabaseril | HMDB | | Galastop | HMDB | | Cabergoline diphosphate | HMDB |
|
|---|
| Chemical Formula | C26H37N5O2 |
|---|
| Average Molecular Weight | 451.6043 |
|---|
| Monoisotopic Molecular Weight | 451.294725453 |
|---|
| IUPAC Name | 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea |
|---|
| Traditional Name | cabergoline |
|---|
| CAS Registry Number | 81409-90-7 |
|---|
| SMILES | [H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC |
|---|
| InChI Identifier | InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 |
|---|
| InChI Key | KORNTPPJEAJQIU-KJXAQDMKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as lysergic acids and derivatives. These are alkaloids with a structure based on the lysergic acid skeleton. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Ergoline and derivatives |
|---|
| Sub Class | Lysergic acids and derivatives |
|---|
| Direct Parent | Lysergic acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Lysergic acid or derivatives
- Indoloquinoline
- Benzoquinoline
- Quinoline-3-carboxamide
- Pyrroloquinoline
- Quinoline
- 3-alkylindole
- Indole
- Indole or derivatives
- Isoindole or derivatives
- 3-piperidinecarboxamide
- Piperidinecarboxamide
- N-acyl urea
- Aralkylamine
- Ureide
- Benzenoid
- Piperidine
- Dicarboximide
- Heteroaromatic compound
- Pyrrole
- Urea
- Tertiary amine
- Tertiary aliphatic amine
- Carbonic acid derivative
- Amino acid or derivatives
- Organoheterocyclic compound
- Azacycle
- Carboxylic acid derivative
- Organooxygen compound
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Amine
- Hydrocarbon derivative
- Carbonyl group
- Organic nitrogen compound
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 102 - 104 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.064 g/L | Not Available | | LogP | 2.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.69 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.2475 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.99 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 202.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 644.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 176.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 165.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 176.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 94.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 267.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 302.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 915.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 711.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 145.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1063.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 203.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 249.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 546.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 635.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 45.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3591.9 | Semi standard non polar | 33892256 | | Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3762.4 | Standard non polar | 33892256 | | Cabergoline,1TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4811.9 | Standard polar | 33892256 | | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3481.4 | Semi standard non polar | 33892256 | | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3966.9 | Standard non polar | 33892256 | | Cabergoline,1TMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4859.9 | Standard polar | 33892256 | | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3528.5 | Semi standard non polar | 33892256 | | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 3890.9 | Standard non polar | 33892256 | | Cabergoline,2TMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4534.4 | Standard polar | 33892256 | | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3785.1 | Semi standard non polar | 33892256 | | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3964.5 | Standard non polar | 33892256 | | Cabergoline,1TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4830.0 | Standard polar | 33892256 | | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 3719.2 | Semi standard non polar | 33892256 | | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4195.5 | Standard non polar | 33892256 | | Cabergoline,1TBDMS,isomer #2 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4871.3 | Standard polar | 33892256 | | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 3900.0 | Semi standard non polar | 33892256 | | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4279.6 | Standard non polar | 33892256 | | Cabergoline,2TBDMS,isomer #1 | C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)N(CC)[Si](C)(C)C(C)(C)C)C[C@@H]2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4562.9 | Standard polar | 33892256 |
|
|---|
| General References | - Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson's disease]. Neurologia. 2003 May;18(4):202-9. [PubMed:12721865 ]
- Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs. 2004;64(18):2125-41. [PubMed:15341508 ]
- Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. [PubMed:8951172 ]
- Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL: The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. [PubMed:15330687 ]
|
|---|